Ketamine for Post-operative Analgesia in Hemorrhoidectomy
Launched by UNIVERSITY OF OKLAHOMA · Jan 27, 2020
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the use of ketamine, a medication often used for pain relief and anesthesia, to help reduce pain after surgery for hemorrhoids. The trial will involve about 100 adults who are having a hemorrhoidectomy, which is a surgical procedure to remove hemorrhoids that are causing significant discomfort. Participants will be randomly assigned to receive either ketamine or no ketamine during their surgery, but they won’t know which treatment they received since they will be under anesthesia.
To be eligible for the trial, participants must be adults aged 18 to 100 who are scheduled for surgery to treat Grade III or IV hemorrhoids. However, individuals who cannot have general anesthesia, have certain medical conditions, or have a history of serious mental health issues will not be included. Those who join the study will help researchers understand if ketamine can effectively manage pain after this common surgery, potentially improving recovery for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults aged 18-100
- • Undergoing a hemorrhoidectomy for Grade III or IV hemorrhoids.
- Exclusion Criteria:
- • Inability to undergo general anesthesia
- • Contraindications to hemorrhoidectomy
- • History of schizophrenia or other hallucinatory psychiatric illnesses
- • History of psychosis
- • Chronic narcotic usage defined as either having a pain contract with a pain management specialist and no narcotic usage for one month prior to hemorrhoidectomy.
About University Of Oklahoma
The University of Oklahoma, a leading research institution, is dedicated to advancing healthcare through innovative clinical trials and research initiatives. With a robust network of interdisciplinary experts and state-of-the-art facilities, the university fosters an environment that promotes scientific discovery and the development of new treatments. Its commitment to patient-centered research ensures that clinical trials not only adhere to the highest ethical standards but also aim to address pressing health challenges. By collaborating with various stakeholders, including industry partners and healthcare providers, the University of Oklahoma seeks to translate research findings into tangible benefits for communities, ultimately enhancing the quality of care and improving health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Oklahoma City, Oklahoma, United States
Oklahoma City, Oklahoma, United States
Patients applied
Trial Officials
Steven N Carter, MD
Principal Investigator
University of Oklahoma
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials